• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Breast Cancer - Articles and news items

activity gene cancer breast

Gene activity linked to breast cancer survival

Industry news / 18 August 2016 / The Institute of Cancer Research, London

In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying…

metastatic breast cancer

Lilly and Boehringer Ingelheim take on metastatic breast cancer

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer…


Denosumab may prevent breast cancer in women with BRCA1 gene mutation

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene…


Faslodex demonstrates superiority to Arimidex in Phase III study

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The Phase III FALCON trial compared Faslodex to Arimidex for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women…


Long term benefits of breast cancer drug pertuzumab too uncertain says NICE

Industry news / 20 May 2016 / Katie Sadler

NICE has announced it will not be recommending pertuzumab to treat HER2-positive breast cancer because it is uncertain of the long term benefits for patients.


The vascular remodelling effects of eribulin in advanced breast cancer

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue…


Positive top-line results from the Phase III PALOMA-2 trial

Industry news / 20 April 2016 / Victoria White, Digital Content Producer

Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer…


Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days

Industry news / 11 March 2016 / Victoria White

A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours. The trial set out to study the biological effects of the drug combination by measuring biological markers of cellular proliferation after 11 days of therapy…


AstraZeneca’s Faslodex approved for new indication in the US

Industry news / 8 March 2016 / Victoria White

The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…


Palbociclib plus fulvestrant slows breast cancer spread

Industry news / 3 March 2016 / Victoria White

In a study, some 67% of 347 women given palbociclib plus fulvestrant showed clinical benefit compared with 40% of 174 women given placebo plus fulvestrant…

Ecosystem Diversity Index

Breast cancer treatment pipeline has over 1,000 drugs in development

Industry news / 1 March 2016 / Victoria White

The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research…


FDA approves expanded indication for Pfizer’s Ibrance

Industry news / 23 February 2016 / Victoria White

Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy…


Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +